{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:49:23Z","timestamp":1764402563948},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.vaccine.2012.12.081","type":"journal-article","created":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T17:46:19Z","timestamp":1357839979000},"page":"1496-1502","source":"Crossref","is-referenced-by-count":12,"title":["Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax\u00ae) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip\u00ae) to adults aged \u226560 years: An open-label, randomised trial"],"prefix":"10.1016","volume":"31","author":[{"given":"Ulrich","family":"Zimmermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00ebtan","family":"Gavazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Eymin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet","family":"Soubeyrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.12.081_bib0005","first-page":"13","article-title":"Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2012.12.081_bib0010","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1515\/REVEH.2005.20.4.303","article-title":"Environmentally and occupationally acquired diseases in adolescents and adulthood: control of diphtheria, tetanus, pertussis, and poliomyelitis through regular booster vaccinations--a European perspective","volume":"20","author":"Hofmann","year":"2005","journal-title":"Rev Environ Health"},{"issue":"3 (Suppl.)","key":"10.1016\/j.vaccine.2012.12.081_bib0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/erv.10.27","article-title":"Updated vaccine guidelines for aging and aged citizens of Europe","volume":"9","author":"Michel","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2012.12.081_bib0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1586\/erv.10.29","article-title":"Vaccination in older adults: development of an educational tool, Vaxisenior, in France","volume":"9","author":"Belmin","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2012.12.081_bib0025","first-page":"61","article-title":"[Tetanus, poliomyelitis and diphtheria vaccination coverage in elderly Parisian residents in 2006]","volume":"9","author":"Gergely","year":"2008","journal-title":"Bull Epidemiol Hebdomadaire"},{"key":"10.1016\/j.vaccine.2012.12.081_bib0030","series-title":"The pink book: course textbook","article-title":"Tetanus. Epidemiology and prevention of vaccine-preventable diseases","author":"Centers for Disease Control and Prevention (CDC)","year":"2011"},{"key":"10.1016\/j.vaccine.2012.12.081_bib0035","unstructured":"European Centre for Disease Prevention and Control (ECDC). Annual Epidemiological Report. Reporting on 2009 surveillance data and 2010 epidemic intelligence data; 2011. Available from: http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/1111_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf [last accessed 7.12.12]."},{"key":"10.1016\/j.vaccine.2012.12.081_bib0040","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/01.inf.0000145263.37198.2b","article-title":"Infant pertussis: who was the source","volume":"23","author":"Bisgard","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2012.12.081_bib0045","first-page":"1302","article-title":"Tetanus and pertussis vaccination coverage among adults aged >18 years - United States, 1999 and 2008","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2012.12.081_bib0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/978-0-387-73960-1_7","article-title":"Pertussis immunisation in adolescents and adults","volume":"609","author":"Heininger","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.vaccine.2012.12.081_bib0055","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1016\/j.vaccine.2006.12.047","article-title":"Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults","volume":"25","author":"McNeil","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.12.081_bib0060","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/01.inf.0000258699.64164.6d","article-title":"Transmission of Bordetella pertussis to young infants","volume":"26","author":"Wendelboe","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2012.12.081_bib0065","doi-asserted-by":"crossref","first-page":"6808","DOI":"10.1016\/j.vaccine.2006.06.037","article-title":"Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers","volume":"24","author":"Kaml","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.12.081_bib0070","first-page":"1","article-title":"Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010","volume":"59","author":"Fiore","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2012.12.081_bib0075","doi-asserted-by":"crossref","DOI":"10.2807\/ese.15.12.19525-en","article-title":"Risk groups and other target groups - preliminary ECDC guidance for developing influenza vaccination recommendations for the season 2010-11","volume":"15","author":"Nokleby","year":"2010","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2012.12.081_bib0080","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00006454-200004000-00003","article-title":"Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults","volume":"19","author":"Halperin","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2012.12.081_bib0085","unstructured":"Sanofi Pasteur MSD. Repevax\u00ae Summary of Product Characteristics; 2011. Available from: http:\/\/www.medicines.org.uk\/emc\/medicine\/15256 [last accessed 6.12.12]."},{"key":"10.1016\/j.vaccine.2012.12.081_bib0090","doi-asserted-by":"crossref","first-page":"858","DOI":"10.4161\/hv.9961","article-title":"Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults","volume":"5","author":"Weston","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2012.12.081_bib0095","unstructured":"European Medicines Agency (EMEA). ICH Topic E 6 (R1) guideline for good clinical practice; 2012. Available from: http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002874.pdf [last accessed 7.12.12]."},{"key":"10.1016\/j.vaccine.2012.12.081_bib0100","unstructured":"World Medical Association. WMA Declaration of Helsinki \u2013 ethical principles for medical research involving human subjects; 2012. Available from: http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html [last accessed 7.12.12]."},{"key":"10.1016\/j.vaccine.2012.12.081_bib0105","unstructured":"European Agency for the Evaluation of Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines; 1997. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003945.pdf [last accessed 7.12.12]."},{"key":"10.1016\/j.vaccine.2012.12.081_bib0110","unstructured":"World Health Organization. The immunological basis for immunization series. Module 4: Pertussis Update 2009; 2010. Available from: http:\/\/whqlibdoc.who.int\/publications\/2010\/9789241599337_eng.pdf [last accessed 7.12.12]."},{"key":"10.1016\/j.vaccine.2012.12.081_bib0115","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0264-410X(98)00227-8","article-title":"Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis","volume":"16","author":"Storsaeter","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.12.081_bib0120","first-page":"63","article-title":"Haemagglutination-inhibiting antibody to influenza virus","volume":"115","author":"de Jong","year":"2003","journal-title":"Dev Biol (Basel)"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13000108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13000108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T18:21:41Z","timestamp":1644085301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13000108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0264410X13000108"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.12.081","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}